Enanta Pharmaceuticals Inc. (ENTA) Stock Rating Lowered by Zacks Investment Research
Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.
According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
Separately, JPMorgan Chase & Co. set a $26.00 price objective on Enanta Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 9th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $27.24.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/enanta-pharmaceuticals-inc-enta-stock-rating-lowered-by-zacks-investment-research.html
Enanta Pharmaceuticals (NASDAQ:ENTA) traded down 0.81% during midday trading on Tuesday, hitting $25.74. The company’s stock had a trading volume of 144,615 shares. Enanta Pharmaceuticals has a one year low of $16.75 and a one year high of $41.77. The company has a market cap of $489.96 million, a price-to-earnings ratio of 17.02 and a beta of 0.52. The company’s 50-day moving average is $24.48 and its 200 day moving average is $24.87.
Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, August 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.03. Enanta Pharmaceuticals had a return on equity of 11.31% and a net margin of 32.59%. The business had revenue of $14 million for the quarter, compared to the consensus estimate of $13.07 million. During the same quarter in the prior year, the company earned $0.13 EPS. The business’s revenue was up 20.7% compared to the same quarter last year. On average, analysts predict that Enanta Pharmaceuticals will post $1.02 EPS for the current year.
A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in Enanta Pharmaceuticals by 295.7% in the second quarter. BlackRock Inc. now owns 4,614 shares of the company’s stock worth $102,000 after buying an additional 3,448 shares during the period. Riverhead Capital Management LLC boosted its stake in Enanta Pharmaceuticals by 1,505.1% in the second quarter. Riverhead Capital Management LLC now owns 6,292 shares of the company’s stock worth $324,000 after buying an additional 5,900 shares during the period. Adams Diversified Equity Fund Inc. acquired a new stake in Enanta Pharmaceuticals during the second quarter worth approximately $194,000. DekaBank Deutsche Girozentrale boosted its stake in Enanta Pharmaceuticals by 1.1% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 9,500 shares of the company’s stock worth $318,000 after buying an additional 100 shares during the period. Finally, Pacad Investment Ltd. boosted its stake in Enanta Pharmaceuticals by 15.3% in the first quarter. Pacad Investment Ltd. now owns 9,800 shares of the company’s stock worth $288,000 after buying an additional 1,300 shares during the period. Institutional investors own 70.82% of the company’s stock.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.